Ahead of the CPhI Worldwide in Madrid next week, Nemaura announced that it would be showcasing its newly developed 48-hour diclofenac transdermal patch and would be linking up with an unnamed global pharma company to develop three new products.
Shire Pharmaceuticals has acquired exclusive development rights to
a new transdermal patch product for Attention-Deficit/Hyperactivity
Disorder (ADHD), adding a further novel product to its ADHD
A novel drug delivery system that allows hospital patients to
self-administer pain relief medication without an intravenous line
could be available in the US within six months, pending final Food
and Drug Administration (FDA) approval.
Australian drug delivery company Acrux, which specialises in
administering medicines through the skin, has reported clinical
results of a contraceptive for women in the form of a spray,
reports Phil Taylor.
TransPharma Medical has entered into collaboration with Teva
Pharmaceutical to develop transdermal drug delivery systems. The
deal aims to research and develop transdermal delivery of
therapeutic drugs such as high molecular weight...
Australian drug delivery company Acrux is hoping to raise A$30
million (€18m) in a float on the Australian Stock Exchange to
support the development of its novel transdermal technology that
does not require the use of adhesive patches...